Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Galapagos 200 euro per aandeel
Volgen
Why Gilead Stock Is a Sleepy Giant Waiting to Break Out InvestorPlace Chris Lau InvestorPlaceSeptember 17, 2018 Rheumatoid Arthritis Treatment Looks Promising Gilead’s Filgotinib drug, which treats patients who have rheumatoid arthritis and previously failed to respond to or were intolerant of biologic agents, met the primary endpoints of a Phase 3 study, Gilead recently reported. The study evaluated Filgotinib, a JAK1 inhibitor, in adult subjects. Compared to the placebo, a statistically significant proportion of the patients’ rheumatoid arthritis symptoms improved at least 20%. The positive results suggest that the company has a blockbuster product in the making. More importantly, compared to the RA drug made by AbbVie Inc. (NYSE:ABBV), Gilead’s treatment has a better safety profile and is more effective. (However, there are no trials that directly compare the two drugs.) Further, the relatively clean safety numbers of Gilead’s drug should help it compete effectively with AbbVie’s product.finance.yahoo.com/news/why-gilead-sto...
3.3.11. Filgotinib - EMEA-001619-PIP04-17-M01 Gilead Sciences International Ltd.; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis, and juvenile idiopathic arthritis) / Treatment of juvenile idiopathic arthritis Day 30 discussion Action: For discussion Immunology-Rheumatology-Transplantation Paediatric Committee (PDCO) Draft agenda for the meeting on 18-21 September 2018 Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga 18 September 2018, 14:00-19:00, room 3A 19 September 2018, 08:30- 19:00, room 3A 20 September 2018, 08:30- 19:00, room 3A 21 September 2018, 08:30- 13:00, room 3A Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.www.ema.europa.eu/docs/en_GB/document...
Zo langzamerhand gaat koers Galapagos tweede col van 200 euro bestijgen. Gilead should also be able to generate attractive sales numbers with some of its pipeline candidates, Filgoinib most likely being the most relevant one in the near term. A couple of days ago Gilead announced that the drug, which is developed with Galapagos NV (GLPG), has shown strong results in a phase III trial for the treatment of rheumatoid arthritis. Due to positive results, it is likely that the drug will receive approval for RA in the foreseeable future, approval in other indications is relatively likely as well. Since the RA market alone is worth $30 billion, even a relatively small market share can result in billions in annual sales in this indication alone. Other indications the drug is targeting, such as ulcerative colitis and Crohn's, are possibly worth billions as well, so it is highly possible that Gilead will be able to generate several billions of dollars in annual revenues from Filgotinib a couple of years down the road.seekingalpha.com/article/4207555-next...
Q3/September Schedule GALAPAGOS NV/S ADR (NASDAQ: GLPG) is due to release Phase 2 data for its combo treatment GLPG 2451+2222+2737 for cystic fibrosis in homozygous F508del patients. Deze week dan maar.m.benzinga.com/article/12390472?utm_r...
Onno van der Stolpe, CEO van Galapagos, het spannendste biotech bedrijf van Nederland is de hoofdgast deze avond. Na de pauze volgt een interview met Onno van der Stolpe (Galapagos). Hoe gaat het met Galapagos? Wat zijn de vooruitzichten? Hoe bevalt de samenwerking met Gilead?www.onlineseminar.nl/rtlz/webinar/235...
A New "Super Drug" Will Send This Biotech Stock Skyrocketingmoneymorning.com/2018/09/26/a-new-sup...
@inspirator in verleden vond ik je commentaar op de ceo Onno heel onfatsoenlijk maar ik wil wel complimenteren met deze postings hierboven dat is informatie waar we wat aan hebben. Thx-))
These assumptions provided us with a Terminal value of the company at €7.6 billion. Our base case stock valuation stood at €159, which is equivalent to approximate $185 at the current exchange rate. This valuation gives us approximately 50 percent upside from current levels. Our bull case presents a price target of €201 or about $235 at today’s exchange rate. This represents an almost 100% increase from current prices.seekingalpha.com/article/4207103-gala...
Positive JAK1 Inhibitor Results On Sept. 11, Gilead stock reported, along with its collaboration partner Galapagos NV, positive results for its Phase 3 clinical trial called FINCH 2. This study looks at JAK1 inhibitor filgotinib in patients suffering from RA (moderate-to-severe active rheumatoid arthritis). At the end of 12 weeks, a statistically significant portion of the subjects exhibited a 20% improvement in RA symptoms compared to the placebo. These results set Gilead stock up for launching a blockbuster drug. The results suggest filgotinib will compete well against the alternative treatments. This includes upadacitinib that AbbVie (NYSE: ABBV) is studying for RA treatment. Filgotinib is also a leading contender for treating Crohn’s disease. If this oral drug reaches the market, Gilead could enjoy a $10 billion Crohn market by 2025. Getting back to the drug’s potential for the RA market, the safety profile and efficacy looks good. Investors should applaud the company for its solid results.investorplace.com/2018/10/5-reasons-t...
Filgotinib is a selective inhibitor of JAK1 over JAK2, JAK3 and TYK2. The rationale for the development of more selective inhibitors such as filgotinib is that less selective JAK inhibitors lead to pan-JAK inhibition that might generate dose-limiting side effects. Published results of Phase II studies in patients with insufficient response to MTX showed that filgotinib was superior to placebo with an acceptable safety profile.17,18 It has also shown efficacy as monotherapy. JAK inhibitors in the treatment of rheumatoid arthritis Related articles Novel treatments in the management of myositis Optimising management of systemic lupus erythematosus Treating giant cell arteritis International updates and 2017 criteria of the Ehlers-Danlos syndromes Challenges in the management of psoriatic arthritis 2 October, 2018 12:04 PMwww.hospitalhealthcare.com/rheumatolo...
Biotechnologiebedrijf Galapagos en verzekeraar Ageas zijn de Belgische aandelen met de meeste potentie in oktober.www.beursduivel.be/Column/285023/Okto...
Volgens de regels van het warrantuitoefeningsprogramma van het directiecomité van Galapagos, dat erin voorziet dat leden van het directiecomité automatisch een minimum aantal warrants uitoefenen onder bepaalde voorwaarden, heeft CEO Onno van de Stolpe 15.000 warrants uitgeoefend. Drie andere leden van het directiecomité hebben in het totaal 15.000 warrants uitgeoefend.
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards Conclusion: In this phase 3 study of pts with highly active RA and prior inadequate response/intolerance to bDMARDs, treatment with FIL over a 24-week period was associated with significant improvement in the signs and symptoms of RA, with a safety profile consistent with Phase 2 data. FIL may provide a novel treatment option for pts who continue to have active RA despite prior biologic therapies.acrabstracts.org/abstract/safety-and-...
De geboorte van volgende Galapagoskindje is aanstaande. Nu al een week overgedragen.www.biopharmcatalyst.com/calendars/fd...
inspirator schreef op 6 oktober 2018 09:14 :
De geboorte van volgende Galapagoskindje is aanstaande.
Nu al een week overgedragen.
www.biopharmcatalyst.com/calendars/fd... Onno vd Stolpe is al opgepiept voor de bevalling.
Zo te zien zijn alle hefboombeleggertjes knockout. Zien de echte beleggers weer een Galapagiskoers van 200 euro in vooruitzicht.
Het spectaculair groeiende biotechnologiebedrijf Galapagos gaat miljoenen investeren in Mechelen. Eind 2021 vestigt het zijn nieuwe internationale hoofdkantoor aan het station, waardoor het de komende jaren kan groeien tot 750 werknemers. Op korte termijn komen er 150 mensen bij. Dat schrijven de kranten van Mediahuis vandaag. De beurswaarde van Galapagos, een Belgisch-Nederlands farmaceutisch researchbedrijf, steeg midden september in één dag met 17 procent. Vandaag is het ongeveer vijf miljard euro waard, een verdubbeling in twee jaar tijd. Dat succes is toe te schrijven aan de veelbelovende resultaten van Filgotinib, een medicijn tegen ontstekingsziekten zoals reuma. In de hoofdzetel in Mechelen-Noord werken vandaag 350 mensen. Daar is Galapagos ondertussen bijna twintig jaar gevestigd. Lees ook “Biotech is geen sector als een ander” Verschillende locaties Omdat het bedrijf verspreid zit over verschillende locaties wil het nu een nieuwbouw realiseren. Eerder deze week werd een overeenkomst gesloten voor de aankoop van een terrein achter het Mechelse station, zo bevestigt COO Bart Filius in de kranten. In een eerste fase zal een gebouw van 24.000 m2 worden opgetrokken. Daarin komen niet alleen kantoren, maar ook hoogtechnologische laboratoria voor onderzoek. Bovendien biedt de nieuwbouw perspectieven om tegen eind 2021 uit te groeien tot een bedrijf van 500 werknemers, met de flexibiliteit om nog uit te breiden tot 750 mensen.
inspirator schreef op 29 september 2018 18:36 :
These assumptions provided us with a Terminal value of the company at €7.6 billion. Our base case stock valuation stood at €159, which is equivalent to approximate $185 at the current exchange rate. This valuation gives us approximately 50 percent upside from current levels. Our bull case presents a price target of €201 or about $235 at today’s exchange rate. This represents an almost 100% increase from current prices.
seekingalpha.com/article/4207103-gala... Koers 200 euro Galapagos komt weer in zicht.
Komt dichtbij. GALAPAGOS NV/S ADR (NASDAQ: GLPG) is due to release Phase 2 data for its combo treatment GLPG 2451+2222+2737 for cystic fibrosis in homozygous F508del patients.m.benzinga.com/article/12487249?utm_r...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)